Knights of Columbus Asset Advisors LLC Grows Position in Haemonetics Co. (NYSE:HAE)

Knights of Columbus Asset Advisors LLC lifted its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 345.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 44,561 shares of the medical instruments supplier's stock after acquiring an additional 34,556 shares during the period. Knights of Columbus Asset Advisors LLC owned approximately 0.09% of Haemonetics worth $3,810,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in HAE. Vanguard Group Inc. raised its position in Haemonetics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier's stock worth $482,017,000 after purchasing an additional 27,146 shares during the period. Kingdon Capital Management L.L.C. purchased a new position in Haemonetics in the 3rd quarter worth $9,952,000. Lazard Asset Management LLC raised its position in Haemonetics by 114.2% in the 3rd quarter. Lazard Asset Management LLC now owns 38,538 shares of the medical instruments supplier's stock worth $3,452,000 after purchasing an additional 20,550 shares during the period. Los Angeles Capital Management LLC raised its position in Haemonetics by 1.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 53,058 shares of the medical instruments supplier's stock worth $4,753,000 after purchasing an additional 586 shares during the period. Finally, Eagle Asset Management Inc. raised its position in Haemonetics by 2.6% in the 3rd quarter. Eagle Asset Management Inc. now owns 268,643 shares of the medical instruments supplier's stock worth $24,065,000 after purchasing an additional 6,828 shares during the period. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Down 2.7 %

HAE traded down $2.22 during midday trading on Friday, reaching $81.24. The company's stock had a trading volume of 845,073 shares, compared to its average volume of 390,265. The firm has a market capitalization of $4.13 billion, a price-to-earnings ratio of 33.02, a PEG ratio of 1.92 and a beta of 0.36. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $95.26. The stock's 50-day moving average is $78.97 and its 200-day moving average is $82.67.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The business had revenue of $336.20 million for the quarter, compared to analysts' expectations of $320.84 million. During the same quarter in the prior year, the company earned $0.85 earnings per share. The business's revenue was up 10.1% compared to the same quarter last year. As a group, research analysts expect that Haemonetics Co. will post 3.95 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Barrington Research reissued an "outperform" rating and issued a $105.00 price target on shares of Haemonetics in a research note on Friday, April 12th. Finally, TheStreet downgraded shares of Haemonetics from a "b-" rating to a "c+" rating in a research note on Thursday, February 29th.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.